Tumors with mutations in genes involving homologous recombination such as BRCA2 are sensitive to PARP inhibition, with a recent phase II study demonstrating biochemical, radiological, and survival benefits in patients with BRCA2-mutant prostate cancer (McCabe et al. 2006; Mateo et al. 2015). The gene discussed is BRCA2; the disease is prostate cancer.